hemodialysis. Extracorporeal dialysis
Conditions
Interventions
Intervention 1: Intervention group receives vial vit C 500mg/5cc intravenously at the end of hemodialysis 3 times a week for a period of 8 weeks. Intervention 2: Control group receives 5cc Normal Sali
Treatment - Drugs
Placebo
Intervention group receives vial vit C 500mg/5cc intravenously at the end of hemodialysis 3 times a week for a period of 8 weeks
Control group receives 5cc Normal Salin at the end of hemodialysis 3 times a week for a period of 8 weeks
Sponsors
Mazandaran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
20 Years to 70 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Signing informed consent, Being on hemodialysis three times a week for at least 6 months prior to the study, age 20-70 years old. Exclusion criteria: Refusal at any time to continue the study, History of Infectious diseases and hospitalization within 2 months prior to the trial, History of vit E, vit C, alcohol & oil fish consumption within 2 months prior to the trial, History of renal transplantation, History of immunosuppressive drugs consumption within 2 months prior to the trial, History of severe neuropsychology, cardiac, respiratory, liver disease or malignancy, Systemic disease during the study
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sleep quality. Timepoint: before intervention and two months later. Method of measurement: PSQI=Pittsburgh sleep quality index. | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum CRP. Timepoint: before intervention and two months later. Method of measurement: mg/l-laboratory kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmir Emami Zeidi
Mazandaran University Of Medical Sciences
Outcome results
None listed